ABIONYX Pharma SA (609) Stock Price & Analysis
609 Stock Chart & Stats
- Day’s Range
- EUR 1.62 - EUR 1.62
- 52-Week Range
- EUR 1.37 - EUR 4.36
- Previous Close
- EUR 1.60
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 70.84M
- Enterprise Value
- EUR 62.06M
- Total Cash (Recent Filing)
- EUR 26.87M
- Total Debt (Recent Filing)
- EUR 15.18M
- Price to Earnings (P/E)
- ―
- Beta
- -0.32
- Next Earnings
- Mar 16, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Specialized Therapeutic Platform
ABIONYX has a defined biological platform rather than an undifferentiated drug-development strategy. Concentrating on apoA-I and HDL-mimetic approaches may support cumulative expertise, focused research priorities, and multiple potential applications in severe inflammatory and infectious diseases.
Revenue Above Historical Base
Although revenue remains small and recently volatile, its level above the company’s earlier near-zero base indicates that ABIONYX has progressed beyond having no commercial or development-related revenue activity. This provides a foundation for future growth if programs advance and revenue becomes more consistent.
Positive Equity Position
Maintaining positive equity gives ABIONYX some balance-sheet support while it develops its pipeline, despite substantial pressure from losses. This is more resilient than an already-negative equity position and may preserve some capacity to fund operations or pursue financing during the next several months.
Bears Say
Severe Operating Losses
The company has not demonstrated a sustainable earnings model: operating losses remain very large relative to revenue, while gross margin fell to about 9% in 2025. Persistent losses can consume capital and make future progress dependent on successful clinical or commercial execution.
Persistent Cash Burn
Consistently negative operating and free cash flow indicates that the business is not currently self-funding. Continued cash consumption, which broadly tracks net losses, increases the importance of a step-change in revenue or costs and can require recurring external financing to sustain development.
Rising Leverage And Eroding Equity
Higher leverage alongside declining equity reduces financial flexibility at a time when the company is still loss-making and cash-burning. The weaker capital base leaves less room to absorb setbacks or fund development internally, increasing the structural pressure on future financing and capital allocation.
609 FAQ
What was ABIONYX Pharma SA’s price range in the past 12 months?
What is ABIONYX Pharma SA’s market cap?
When is ABIONYX Pharma SA’s upcoming earnings report date?
How were ABIONYX Pharma SA’s earnings last quarter?
Is ABIONYX Pharma SA overvalued?
Does ABIONYX Pharma SA pay dividends?
What is ABIONYX Pharma SA’s EPS estimate?
How many shares outstanding does ABIONYX Pharma SA have?
What happened to ABIONYX Pharma SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of ABIONYX Pharma SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
ABIONYX Pharma SA
ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This compound is designed to mimic the structural and functional attributes of pre-beta HDL, utilizing human recombinant apoA-I (a natural high-density lipoprotein protein) along with natural phospholipids like sphingomyelin and dipalmitoylphosphatidylglycerol. CER-001 is currently under development for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Another key candidate, CER-002, is a specific agonist for peroxisome proliferator-activated receptor delta, targeting cardiovascular and metabolic diseases. Additionally, CER-209 is being developed as a potential treatment for metabolic liver diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). ABIONYX maintains strategic partnerships with GTP Biologics and VBI Therapeutics Group for the bioproduction of its bio-HDL in France. Established in 2005, the company operated as Cerenis Therapeutics Holding SA before its rebranding to ABIONYX Pharma SA in August 2019. Its operations are headquartered in Balma, France.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Cyrille Tupin
- Employees
- 49
- Website
- abionyx.com
- Address
- Building D2, Balma, OC, 31130, FR
ABIONYX Pharma SA (609) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 2 | 10 |
| Technical Analysis | 3 | 2 | 4 |
| Moving Averages | 6 | 0 | 6 |
